Lung cancer Archives - Healthcare Communications Network

American Medical AssociationAssociation Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer

In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials.

HMP CommunicationsDurvalumab Reduces Mortality Risk vs Chemo in NSCLC With PD-L1 Expression

Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.

HMP CommunicationsAnti–PD-L1 Therapy Not Recommended for Patients w. NSCLC, Active Brain Metastases

Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic […]

Wyanoke GroupUSPSTF: Start Lung Cancer Screening Earlier

In addition to reducing pack-years history of smoking, the recommendation calls for annual screening for lung cancer at age 50 years instead of age 55 years, an update of the U.S. Preventive Services Task Force (USPSTF) guidance on lung cancer screening issued 7 years ago.

HMP CommunicationsFirst-Line Pembrolizumab Combo Improves PFS in Patients w. Extensive-Stage SCLC

The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC.

Haymarket MediaALK-Rearranged NSCLC Linked to Higher Venous and Arterial Thrombotic Risk

The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.

Haymarket MediaFoundationOne CDx Approved as Companion Diagnostic for Capmatinib for METex14 NSCLC

The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.

Haymarket MediaLow-Dose Erlotinib an Option for Frail or Elderly Patients w. NSCLC?

According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.

HMP CommunicationsFDA Approves Lurbinectedin for Adults With Metastatic SCLC

Based on monotherapy data from an open-label, multi-center, single-arm study of 105 adults with platinum-sensitive and platinum-resistant SCLC that progressed after platinum-based chemotherapy, the FDA granted accelerated approval to lurbinectedin (Zepzelca; Jazz Pharmaceuticals and PharmaMar).

Caribou PublishingASCO20 Plenary Sessions

On May 31, 2020, at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Sessions, late-breaking data dropped for three potentially practice-changing studies: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.